ClinicalTrials.gg
CompletedNCT03767738Updated Sep 16, 2021Results posted

Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe

A Phase 4 interventional study of Intravitreal Aflibercept Injection (IAI) in Chorioretinal Vascular Disease, sponsored by Regeneron Pharmaceuticals. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-16.

Sponsored by Regeneron Pharmaceuticals · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
65
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of the study is to determine if the pre-filled syringe (PFS) supports successful preparation and accurate administration of an aflibercept injection.

The secondary objective of the study is to assess ocular safety in the study eye.

02

Conditions studied

  • Chorioretinal Vascular Disease
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants who have neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), or diabetic retinopathy (DR) with diabetic macular edema (DME) in the study eye

Key Exclusion Criteria:

  • Evidence of active infectious blepharitis, keratitis, scleritis, or conjunctivitis in either eye
  • Any active intraocular inflammation or infection in either eye or history of intraocular inflammation or infection after past intravitreal injection treatment (IVT) injections with any agent in either eye
  • History of or any current indication of excessive bleeding and recurrent hemorrhages, including any prior excessive intraocular (including subconjunctival) bleeding or hemorrhages after IVT injection or intraocular procedures in either eye
  • Any intraocular surgery in the study eye at any time during the past 3 months
  • Current systemic infectious disease or a therapy for active infectious disease
  • Pregnant or breastfeeding women

Note: Other inclusion/ exclusion apply

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Intravitreal Aflibercept Injection (IAI)

    Cohort 1 - Initial patients Cohort 2 - Additional patients

    Drug: Intravitreal Aflibercept Injection (IAI)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Aflibercept Injections Successfully Administered Utilizing the Prefilled Syringe (PFS)

    Participants received a single dose of study drug, administered in the selected study eye with the PFS by a retina specialist. Physician assessed successful aflibercept preparation and administration with the PFS.

    Time frame: At Day 1

Secondary outcomes

  1. Incidence of Ocular Treatment-Emergent Adverse Events (TEAEs) of Study Eye Through Day 29

    A treatment emergent AE (TEAE) is an adverse event starting after study eye injection and no later than 28 days after administration of study medication.

    Time frame: Baseline through Day 29

  2. Incidence of Ocular Serious TEAEs of Study Eye Through Day 29

    A serious treatment emergent AE (TEAE) is a serious adverse event starting after study eye injection and no later than 28 days after administration of study medication.

    Time frame: Baseline through Day 29

07

Results

Posted Sep 16, 2021

Participant flow

A total of 65 participants were enrolled in the United States.

Participant flow — Overall Study
MilestoneCohort 1: Intravitreal Aflibercept Injection (IAI) 2 mgCohort 2: IAI 2 mg
Started3530
Completed3530
Not completed00

Outcome measures

PrimaryNumber of Aflibercept Injections Successfully Administered Utilizing the Prefilled Syringe (PFS)

Participants received a single dose of study drug, administered in the selected study eye with the PFS by a retina specialist. Physician assessed successful aflibercept preparation and administration with the PFS.

Time frame:
At Day 1
Reported as:
Number · Injections
Number of Aflibercept Injections Successfully Administered Utilizing the Prefilled Syringe (PFS)
InjectionsCohort 1: Intravitreal Aflibercept Injection (IAI) 2 mgCohort 2: IAI 2 mg
Number of Aflibercept Injections Successfully Administered Utilizing the Prefilled Syringe (PFS)3529
SecondaryIncidence of Ocular Treatment-Emergent Adverse Events (TEAEs) of Study Eye Through Day 29

A treatment emergent AE (TEAE) is an adverse event starting after study eye injection and no later than 28 days after administration of study medication.

Time frame:
Baseline through Day 29
Reported as:
Number · Events
Incidence of Ocular Treatment-Emergent Adverse Events (TEAEs) of Study Eye Through Day 29
EventsCohort 1: Intravitreal Aflibercept Injection (IAI) 2 mgCohort 2: IAI 2 mg
Conjunctival haemorrhage31
Eye irritation30
Dry eye01
Eye pain01
Lenticular opacities01
Corneal abrasion10
SecondaryIncidence of Ocular Serious TEAEs of Study Eye Through Day 29

A serious treatment emergent AE (TEAE) is a serious adverse event starting after study eye injection and no later than 28 days after administration of study medication.

Time frame:
Baseline through Day 29
Reported as:
Number · Events
Incidence of Ocular Serious TEAEs of Study Eye Through Day 29
EventsCohort 1: Intravitreal Aflibercept Injection (IAI) 2 mgCohort 2: IAI 2 mg
Incidence of Ocular Serious TEAEs of Study Eye Through Day 2900

Adverse events

Collected over Up to Day 29. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Intravitreal Aflibercept Injection (IAI) 2 mg0/35 (0%)1/35 (2.9%)6/35 (17.1%)
Cohort 2: IAI 2 mg0/30 (0%)0/30 (0%)1/30 (3.3%)
Most frequent serious events
Most frequent serious events
EventCohort 1: Intravitreal Aflibercept Injection (IAI) 2 mgCohort 2: IAI 2 mg
Iron deficiency anaemiaBlood and lymphatic system disorders1/350/30
Most frequent other events
Most frequent other events
EventCohort 1: Intravitreal Aflibercept Injection (IAI) 2 mgCohort 2: IAI 2 mg
Conjunctival haemorrhage Study EyeEye disorders3/351/30
Eye irritation Study EyeEye disorders3/350/30

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort 1: Intravitreal Aflibercept Injection (IAI) 2 mgCohort 2: IAI 2 mgTotal
Mean72.2 ± 10.0464.7 ± 13.4468.8 ± 12.23
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Intravitreal Aflibercept Injection (IAI) 2 mgCohort 2: IAI 2 mgTotal
Female201434
Male151631
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Intravitreal Aflibercept Injection (IAI) 2 mgCohort 2: IAI 2 mgTotal
Hispanic or Latino347
Not Hispanic or Latino322658
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: Intravitreal Aflibercept Injection (IAI) 2 mgCohort 2: IAI 2 mgTotal
White322557
Black or African American336
Asian011
American Indian or Alaska Native000
Native Hawaiian or Other Pacific Islander000
Other011
Not Reported000
08

Study locations

2 sites
  • Regeneron Study Site
    Houston, Texas 77030, United States
  • Regeneron Study Site
    The Woodlands, Texas 77384, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in Aug 2020, 20 months.

Results were first posted in Sep 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2018
First posted
Dec 7, 2018
StartActual
Dec 19, 2018
Primary completionActual
Aug 19, 2020
CompletionActual
Aug 19, 2020
Results first posted
Sep 16, 2021
Last update
Sep 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03767738
Responsible party
Sponsor
First posted
Dec 7, 2018
Start date
Dec 19, 2018
Primary completion
Aug 19, 2020
Completion
Aug 19, 2020
Results posted
Sep 16, 2021
Last update
Sep 16, 2021

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion